132 related articles for article (PubMed ID: 34292567)
21. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
22. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course.
Zeltzer PM; Marangos PJ; Evans AE; Schneider SL
Cancer; 1986 Mar; 57(6):1230-4. PubMed ID: 3002599
[TBL] [Abstract][Full Text] [Related]
23. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
24. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments.
Korse CM; Taal BG; Vincent A; van Velthuysen ML; Baas P; Buning-Kager JC; Linders TC; Bonfrer JM
Eur J Cancer; 2012 Mar; 48(5):662-71. PubMed ID: 21945100
[TBL] [Abstract][Full Text] [Related]
25. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Kaltsas GA; Papadogias D; Makras P; Grossman AB
Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
Hvamstad T; Jordal A; Hekmat N; Paus E; Fosså SD
Eur Urol; 2003 Aug; 44(2):215-21. PubMed ID: 12875941
[TBL] [Abstract][Full Text] [Related]
27. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.
Pujol JL; Boher JM; Grenier J; Quantin X
Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401
[TBL] [Abstract][Full Text] [Related]
28. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic value of neuron specific enolase (NSE) in the cerebrospinal fluid of malignant brain tumor with intrathecal metastasis].
Miyagami M; Tazoe M; Tsubokawa T
No To Shinkei; 1989 Oct; 41(10):1021-7. PubMed ID: 2605041
[TBL] [Abstract][Full Text] [Related]
30. The clinical value of neuron-specific enolase as a tumor marker in bronchoalveolar lavage.
Prados MC; Alvarez-Sala R; Blasco R; Chivato T; García Satué JL; García Río FJ; Gómez de Terrero FJ; Villamor J
Cancer; 1994 Sep; 74(5):1552-5. PubMed ID: 8062188
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
Oberg K
Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
[TBL] [Abstract][Full Text] [Related]
32. Immunocytochemical localization of neuron specific enolase in small cell carcinomas and carcinoid tumours of the lung.
Sheppard MN; Corrin B; Bennett MH; Marangos PJ; Bloom SR; Polak JM
Histopathology; 1984 Mar; 8(2):171-81. PubMed ID: 6202617
[TBL] [Abstract][Full Text] [Related]
33. Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma.
van de Pol M; Twijnstra A; ten Velde GP; Menheere PP
J Neurooncol; 1994; 19(2):149-54. PubMed ID: 7964990
[TBL] [Abstract][Full Text] [Related]
34. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
[No Abstract] [Full Text] [Related]
35. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
[TBL] [Abstract][Full Text] [Related]
36. Neuron-specific enolase in mucosal endocrine cells and carcinoid tumours of the small intestine: a comparative study with neuron-specific enolase immunocytochemistry and silver stains.
Lundqvist M; Wilander E; Esscher T; Påhlman S
Histochem J; 1985 Mar; 17(3):323-31. PubMed ID: 2411685
[TBL] [Abstract][Full Text] [Related]
37. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H; Honma Y; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Kato K; Fukuda T; Boku N
Invest New Drugs; 2019 Jun; 37(3):573-578. PubMed ID: 30267338
[TBL] [Abstract][Full Text] [Related]
39. Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours.
Rodrigues M; Gabriel M; Heute D; Putzer D; Griesmacher A; Virgolini I
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1796-802. PubMed ID: 18425512
[TBL] [Abstract][Full Text] [Related]
40. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]